On 08th September 2025, the U.S. Food and Drug Administration (FDA) published its final guidance for industry on ICH E6(R3) Good Clinical Practice. This guidance aligns with the new ICH principles and aims to support adoption of flexible, risk-based approaches, and promotes innovations in trial design, conduct, and use of technology.

E6(R3) Good Clinical Practice (GCP) | FDA